Dupilumab in Adolescents With Moderate-to-Severe Atopic Dermatitis and a History of Allergic Rhinitis: Subgroup Analysis From a Phase 3 Trial

Atopic dermatitis (AD) is a chronic inflammatory skin disease commonly associated with other atopic conditions such as allergic rhinitis (AR). Dupilumab is approved in the USA for adults and adolescents with inadequately controlled moderate-to-severe AD; as an add-on maintenance treatment for adults and adolescents with inadequately controlled eosinophilic/oral corticosteroid-dependent asthma; and as an add-on maintenance treatment in adults with inadequately controlled chronic rhinosinusitis with nasal polyps.

Source: Journal of Allergy and Clinical Immunology - January 31, 2020 Category: Allergy & Immunology Authors: Lawrence Sher, Weily Soong, Paola Mina-Osorio, Randy Prescilla, Zhen Chen, Ashish Bansal Source Type: research